Income Tax Expense (Benefit) in USD of Barinthus Biotherapeutics plc. from 2020 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Barinthus Biotherapeutics plc. quarterly/annual Income Tax Expense (Benefit) history and change rate from 2020 to Q3 2025.
  • Barinthus Biotherapeutics plc. Income Tax Expense (Benefit) for the quarter ending 30 Sep 2025 was -$71K, a 2267% decline year-over-year.
  • Barinthus Biotherapeutics plc. Income Tax Expense (Benefit) for the twelve months ending 30 Sep 2025 was -$115K, a 86.7% increase year-over-year.
  • Barinthus Biotherapeutics plc. annual Income Tax Expense (Benefit) for 2024 was -$44K, a 98.6% increase from 2023.
  • Barinthus Biotherapeutics plc. annual Income Tax Expense (Benefit) for 2023 was -$3.08M, a 31.2% increase from 2022.
  • Barinthus Biotherapeutics plc. annual Income Tax Expense (Benefit) for 2022 was -$4.47M, a 15868% decline from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)

Barinthus Biotherapeutics plc. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$115K -$71K -$68K -2267% 01 Jul 2025 30 Sep 2025 10-Q 07 Nov 2025
Q2 2025 -$47K -$25K -$18K -257% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 -$29K -$22K +$15K +40.5% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025
Q4 2024 -$44K $3K +$823K 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025
Q3 2024 -$867K -$3K +$600K +99.5% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2025
Q2 2024 -$1.47M -$7K +$1.13M +99.4% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 -$2.6M -$37K +$479K +92.8% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025
Q4 2023 -$3.08M -$820K +$1.2M +59.4% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025
Q3 2023 -$4.27M -$603K +$71K +10.5% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024
Q2 2023 -$4.35M -$1.14M -$221K -24.2% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024
Q1 2023 -$4.12M -$516K +$347K +40.2% 01 Jan 2023 31 Mar 2023 10-Q 13 May 2024
Q4 2022 -$4.47M -$2.02M -$2.05M -6409% 01 Oct 2022 31 Dec 2022 10-K 20 Mar 2024
Q3 2022 -$2.42M -$674K -$667K -9529% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$1.75M -$915K -$927K -7725% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023
Q1 2022 -$826K -$863K -$798K -1228% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023
Q4 2021 -$28K $32K 01 Oct 2021 31 Dec 2021 10-K 24 Mar 2023
Q3 2021 -$7K 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022
Q2 2021 $12K 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022
Q1 2021 -$65K 01 Jan 2021 31 Mar 2021 10-Q 11 May 2022

Barinthus Biotherapeutics plc. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$44K +$3.03M +98.6% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025
2023 -$3.08M +$1.4M +31.2% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025
2022 -$4.47M -$4.44M -15868% 01 Jan 2022 31 Dec 2022 10-K 20 Mar 2024
2021 -$28K -$123K -129% 01 Jan 2021 31 Dec 2021 10-K 24 Mar 2023
2020 $95K 01 Jan 2020 31 Dec 2020 10-K 25 Mar 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.